Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeyoND long-term safety study of ND0612 in advanced Parkinson's disease
2024-513548-27-00Phase 2Authorised
- Sponsor
- NeuroDerm Ltd.
- Start
- Jun 2024
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 2, open-label trial of ND0612 in Parkinson's disease (PD) (2 cohorts), sponsored by NeuroDerm Ltd. Primary endpoint: Long-term safety and tolerability of ND0612. Planned start Jun 2024; status: authorised.
02
Drugs
ND0612
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2024-513548-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513548-27-00.